Soligenix published data Thursday demonstrating a “heat-stable” anthrax vaccine called VeloThrax.
The company, a late-stage biopharmaceutical company that develops products to address needs in biodefense, inflammation and oncology, said the vaccine was able to withstand extreme temperatures and didn't need the normal “cold chain requirements” of other anthrax vaccines.
ThermoVax, a vaccine stabilizer, was used to enhance the stability of VeloThrax, the company said. Further studies showed the vaccine working rapidly and that it enhanced immunogenicity.
Animal testing showed that VeloThrax offered positive responses after two doses given in less than month. Other tests have combined VeloThrax with the company's ricin vaccine called RiVax.
Christopher Schaber, president and CEO of Soligenix, said a vaccine that can work in higher temperatures is an advantage over the current vaccines in development.
The studies on VeloThrax were done using a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). Researchers at the University of Colorado, the Wadsworth Center, New York State Department of Health and the University of Kansas all contributed to the work.
Schaber said the company will continue to develop both VeloThrax and RiVax using the same technology with the aid from another NIAID contract worth up to $24.7 million over the next five years.